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ABSTRACT
Purpose: The cellular origin of retinoblastoma is uncertain as constituent tumor 
cells heterogeneously express markers of both immature and mature retinal cells. 
An immunohistochemical analysis of cellular origin may yield valuable insights 
into disease progression and treatment options. This study aimed to determine 
the cellular origin of retinoblastoma in a large case series and correlate these 
findings with histopathological prognostic factors. 
Methods: Thirty-nine retinoblastoma cases were histopathologically diagnosed 
and analyzed by immunohistochemistry using monoclonal antibodies against 
the immature neural cell marker SRY-box containing gene 2 (SOX-2), the mature 
neuronal cell marker microtubule-associated protein 2 (MAP2), and the mature 
glial cell marker glial fibrillary acidic protein (GFAP). Histopathological features 
were also evaluated, including patterns of growth, differentiation, vitreous see ding, 
and choroidal/scleral, optic nerve, and anterior chamber invasion. Two retinoblas-
toma cell lines, WERI-1 and Y79, were studied by immunocytochemistry using 
the same antibodies. 
Results: Expression of SOX-2 was strong in 97.4% of retinoblastoma cases, while 
MAP-2 was expressed in 59% of cases. Immunostaining for GFAP was positive only 
in reactive stromal astrocytes interspersed amongst tumor cells and in peritumoral 
tissue. There was no correlation between histopathological prognostic factors and 
immunohistochemical markers. Retinoblastoma cell lines showed strong positivity 
for SOX2 (90% of WERI-1 cells and 70% of Y79 cells) and MAP2 (90% of cells in both 
lines). GFAP was completely negative in both cell lines.
Conclusion: The majority of retinoblastomas and both RB cell lines expressed an 
immature neural and/or a mature neuronal cell marker, but not a glial marker. These 
results indicate a typical neuroblast or neuronal origin and eliminate astrocyte 
differentiation from neural stem cells as the source of retinoblastoma.
Keywords: Retinoblastoma/etiology; Retinoblastoma/pathology; Phenotype; Prog -
nosis; Immunohistochemistry; Antibodies, monoclonal
RESUMO
Objetivos: Este estudo visa determinar a origem do retinoblastoma em um número 
de casos e correlacionar essos achados com fatores prognósticos e histopatológicos 
conhecidos. 
Métodos: Trinta e nove casos de retinoblastoma foram diagnosticados e analisados 
com imuno-histoquímica usando marcadores de anticorpos monoclonais contra as 
células de retina imaturas (SOX-2: SRY-box containing gene 2), contra as células da retina 
maturas (MAP2: microtubule -associated protein 2) e contra as células gliais maturas 
(GFAP: glial fibrillar acidic protein). Foram avaliadas características microscópicas dos 
casos (grau de diferenciação, presença de semeadura vítrea, invasão de coroide/esclera, 
nervo óptico e câmara anterior). Duas linhas celulares de retinoblastoma (WERI-1 e 
Y79) também foram testadas, utilizando os três marcadores.
Resultados: A expressão de SOX-2 foi positiva em 97,4% dos casos de retinoblastoma, 
enquanto MAP2 foi positivo em 59% dos casos. GFAP foi apenas positivo no estroma 
(astrócitos reativos). Não houve correlação entre preditores histopatológicos e marca-
dores imunohistoquímicos avaliados. As linhagens celulares mostraram positividade 
para SOX-2 (90% em WERI-1 e 70% das células Y79). Ambas as linhagens celulares se 
mostraram fortemente positivas con MAP2 (90%), enquanto não houve expressão de 
GFAP em nenhuma das linhas celulares estudadas. 
Conclusões: A maioria das células de retinoblastoma desta série de casos expressa 
marcadores de células retinianas imaturas, além de marcadores de células maduras. 
As linhas celulares Y79 e WERI-1 apresentaram imunomarcação para ambos os 
marcadores neurais em percentagens semelhantes a dos casos avaliados. Portanto, 
estes resultados confirmam a origem neural do tumor em particular. Alem disso, a 
ausência de células positivas para GFAP no tumor descarta diferenciação de astró-
citos em retinoblastoma.
Descritores: Retinoblastoma/etiologia; Retinoblastoma/patologia; Fenótipo; Prog-
nóstico; Imuno-histoquímica; Anticorpos monclonais
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INTRODUCTION
Retinoblastoma (RB) is the most common intraocular tumor in 
childhood(1,2), and the vast majority of cases (about 80%) are diagno-
sed before the age of three(3). Retinoblastoma originates from a neu -
ro sensitive retina, and despite extensive study for many decades, its 
origin remains controversial(4,5). Various studies posit that the retino-
blastoma cell could be a primitive multipotent cell, a photoreceptor/
glial dual differentiation cell, or strictly a neuronal cell(5-10). Others propose 
the theory that the original cell may be a differentiated photoreceptor, 
specifically a cone(6,8,11,12).
Several molecules have been identified that are expressed only 
at specific times during retinal development, suggesting utility as 
mar kers for cell type and degree of differentiation(13-17). SOX-2 is a 317 
amino acid protein belonging to the family of strong sex determining 
ImmunohIstochemIcal analysIs of retInoblastoma cell phenotype usIng neuronal and glIal cell markers
396 Arq Bras Oftalmol. 2016;79(6):395-9
region Y-box (SOX) transcription factors crucial for maintaining mul-
tipotency of neuroglial stem cells. SOX-2 is strongly expressed by 
neuroepithelial cells during early development of the central nervous 
system(18). Microtubule-associated protein 2 (MAP2) is a 280 kD pro-
tein highly concentrated in the soma and dendrites of mature neu-
rons(13,14,19). Glial fibrillary acidic protein (GFAP) is a marker of mature 
glia, including retinal glia. Studies of expression in retinoblastoma(7-10) 
have detected GFAP in reactive Mϋller cells (reactive astrocytes) sur-
rounding the tumor(13).
In the current study, a series of enucleated and archived reti-
noblastoma samples and two RB cell lines (WERI-1 and Y79) were 
immunostained for markers of immature neural cells (SOX-2), mature 
neuronal cells (MAP2), and astroglial cells (GFAP) to examine cell 
origin and the relationship between marker phenotype and histopa-
thological prognostic factors.
METHODS
Thirty-nine tissue samples of retinoblastoma added to the Henry 
C. Witelson Ocular Pathology Laboratory and Registry files at McGill 
University (Montreal, Canada) from the Instituto Anatomopatológico 
“Dr. José A. O’Daly” of the Universidad Central of Venezuela were 
se lected, and clinical/epidemiological data (age, sex, and eye side) 
collected. No long-term clinical data were available because the re-
quest forms did not contain the information or links to access patient 
medical records. Thus, no comparisons that allowed determination 
of prognosis and survival were conducted.
Some morphological characteristics, such as differentiation status 
of the tumor (differentiated or un-differentiated), choroidal/scleral 
and optic nerve level of invasion (according to the Khelfaoui criteria) 
(Table 1)(15), presence of vitreous seeding, vascular basophilia, and 
anterior chamber invasion were also recorded and re-evaluated.
Two human RB cell lines (WERI-1 and Y79, American Type Culture 
Collection, Manassas, VA, USA) were also examined for marker pheno-
type. These cell lines were cultivated until use according to standard 
procedures.
Immunohistochemistry and immunocytochemistry were con-
ducted using an automated Benchmark® slide staining system (Ven-
tana Medical System, Inc.; Tucson, Arizona). Immunostaining modu-
les for SOX-2, MAP2, and GFAP were used according to protocols and 
instructions provided by the supplier (Ventana Medical System, Inc.). 
All immunostaining protocols were based on a streptavidin-biotin 
complex(20-23).
For positive controls, SOX2 staining was confirmed in fetal retina 
cuts, MAP-2 staining in normal retina of the studied eyeballs, and 
GFAP in normal retina and optic nerve of the studied eyeballs. For 
negative controls, the primary antibody was omitted.
The staining intensity for all antibodies was graded from 0-3, where 
0= negative staining, 1+= weak staining, 2+= moderate staining, and 
3+= strong staining. Positive staining was defined as 2+ or 3+ inten-
sity in the nucleus and cytoplasm for SOX-2 and in the cytoplasm for 
MAP2 and GFAP, while staining intensity of 0+ or 1+ was considered 
negative.
Specimens were independently analyzed by two experienced 
ocular pathologists (M.E.O. and M.N.B. Jr.) who rated the samples on 
two different occasions. They were not aware of prior medical history, 
the results of previous assessments, or evaluation by the other ob-
server. Conflicts in assessment were resolved by mutual agreement 
between the observers, and the final decision was used for statistical 
analysis.
For statistical analysis, frequency and percentage of nominal and 
ordinal variables were calculated. Nominal variables were compared 
by Pearson Chi-square test. Results were considered significant when 
the p value was less than 0.05. The relationships between intensity 
of immunostaining and various histopathological parameters were 
assessed by correlation analysis. A p value less than 0.05 was consi-
dered a statistically significant correlation.
The study protocol was approved by the ethics committees of the 
Federal University of São Paulo (Annex) and McGill University (McGill 
University Health Centre, Montreal, Canada). The use of material from 
the Instituto Anatomopatológico (Caracas, Venezuela) was authori-
zed by the originating section.
RESULTS
The thirty-nine archived tissue samples were obtained from 
patients between 4 and 108 months of age (mean ± SD, 24 ± 21.8 
months; 48% female), with most cases in the range of 4 to 12 months. 
The series included 18 cases of well/moderately differentiated re-
tinoblastoma (46.2%) and 21 cases of poorly differentiated retino-
blastoma (53.8%). The level of choroidal/scleral invasion was stage I 
in 12 cases (30.7%), stage II in 7 (18%), stage III in 13 (33.3%), stage IV 
in 5 (12.8%), and stage V in 2 cases (5.2%). The degree of optic nerve 
invasion was stage I in 9 cases (23%), stage II in 15 (38.5%), stage III 
in 11 (28.2%), and stage IV in 4 cases (10.3%). Vitreous seeding was 
obser ved in 28 cases (71.8%) and invasion of retinoblastoma tumor 
cells into the anterior chamber was observed in 8 cases (20.5%). 
Basophilia of vascular walls, inner limiting membrane of the retina, 
and fibers of Zinn’s zonule was observed in 18% of cases.
Thirty-eight cases showed positive nuclear and cytoplasmic immu-
nostaining for SOX-2 (97.4%) and 23 cases (59%) for MAP2. Both SOX-2 
immunostaining (Figure 1) and MAP immunostaining (Figure 2) were 
also observed in well-differentiated tumor cells corresponding to foci 
of retinocytoma. Most retinoblastoma cases also showed intense 
cytoplasmic immunostaining for GFAP in isolated astrocytes within 
the tumor and in Mϋller cells of uncompromised retina, but tumor 
cells were completely negative for this marker in all cases (Figure 3).
In addition to retinoblastoma tissue, SOX-2 and MAP2 immuno-
reactivity were observed in normal retinal pigment epithelium, inner 
segments of photoreceptors, outer and inner plexiform layers of the 
retina, ganglion cells, nerve fiber layer, optic and ciliary nerves, non- 
pigmented epithelium of the ciliary body, and corneal and limbic 
epithelia. The optic nerve and ciliary nerves also showed positive im-
munostaining for GFAP. These extratumoral staining results confirm 
that all three antibodies efficiently recognize the intended antigens.
There were statistically significant positive associations between 
patient age and both SOX-2 immunostaining (p=0.0045) and MAP2 
immunostaining (p=0.0311). In contrast, no other demographic or 
clinical variable was significantly associated with SOX-2 or MAP-2 
expression status.
Table 1. Choroidal/scleral and optic nerve involvement according to 
the criteria of Khelfaoui et al.(15)
Choroidal/scleral involvement Definition
No choroidal involvement
Minimal involvement Tumor cells having destroyed Bruch’s 
membrane without invading the 
choroid, with a maximum of three 
microscopic cell clusters
Massive involvement Any choroidal involvement that is not 
minimal
Intrascleral involvement Any scleral involvement
Extrascleral involvement (i.e., microscopic orbital involvement)
Optic nerve (ON) involvement
No optic nerve involvement
Prelaminar involvement Anterior to the lamina cribrosa
Postlaminar without invasion of the ON 
resection line or subarachnoid space
Within or beyond the lamina cribrosa
Invasion of the resection line and/or 
subarachnoid space
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Figure 1. Immunoexpression of SOX-2 in retinoblastoma. A) Positive staining in tumor cells forming a pseudovascular 
rosette (arrow) (×400). B) Intense positivity in tumor cell cytoplasm from a differentiated retinoblastoma with fleu-
rettes (arrowheads) and Flexner-Wintersteiner rosettes (arrows) (×200). C) Positive immunostaining in an undifferen-
tiated retinoblastoma. Adjacent endothelial cells (e) are negative (×200). D) Intense staining in an undifferentiated 
retinoblastoma located close to non-tumoral retinal internal limiting membrane and the nerve fiber layer (×320).
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Figure 2. Immunoexpression of MAP2. A) Positive staining in tumor cells forming a pseudovascular rosette (arrow) 
(×320). B) Differentiated retinoblastoma with fleurettes (arrowheads) and Flexner-Wintersteiner rosettes (arrow) with 
intense MAP2 positivity in tumor cell cytoplasm (×400). C) Moderate positivity in an undifferentiated retinoblastoma 
(×400). D) Negative staining in an undifferentiated retinoblastoma (×320).
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SOX-2 was observed in cytoplasm and nucleus of both WERI-1 
and Y79 retinoblastoma cell lines, with more intense immunostai-
ning in the WERI-1 line. MAP2 staining was equivalently strong in the 
cytoplasm of WERI-1 and Y79 cell lines, while GFAP immunostaining 
was negative in both cell lines (Table 2).
DISCUSSION
Identifying the origin of retinoblastoma will advance our unders-
tanding of how cellular context influences the probability of cancer 
initiation and progression by specific mutations (e.g., chromosome 
1q and 6p gain and 16q loss often associated with this tumor). Further, 
knowledge of cellular origin may guide treatment decisions and 
provide clues for improving existing therapies or developing new 
treatments. We found that almost all retinoblastoma samples were 
immunopositive for the immature neural cell marker SOX-2 and the 
majority of samples were immunopositive for the mature neuronal 
marker MAP2, including well-differentiated tumor cells. In contrast, 
none expressed the astroglial marker GFAP, suggesting that neuro-
blastoma originates from cells committed to the neuronal lineage.
During the last ten years, significant advances have been made in 
the epidemiology and clinical management of retinoblastoma, such 
as identification of histopathological markers and tumor suppressors 
like Rb protein and its associated pathways. However, the cellular 
origin of retinoblastoma is still controversial(4,13,24). Molnar et al.(9) 
stu died seven retinoblastoma cases and observed that tumor cells 
stained positively for myelin-associated glycoprotein (GPAM), which 
is only expressed in Müller cells in normal retina, whereas the same 
cells were negative for neuron-specific enolase (NSE) and GFAP, sug-
gesting Müller rather than neuronal or astroglial origin. An important 
factor to consider, however, is the possible existence of a mixed po-
pulation of cells within a tumor. Tarlton et al. studied six retinoblasto-
mas with a panel of 18 monoclonal antibodies covering a wide range 
of tissue types and found marked heterogeneity within each tumor, 
possibly due to multiple intratumoral foci of differentiation(25-27). 
Many molecules are expressed only at specific times during re-
tinal differentiation and can be used as specific markers for cell type 
and degree of differentiation. These include molecules expressed at 
high levels in immature retinal stem cells compared to mature retinal 
cells(13,28). In this study, we observed that retinoblastoma tumor cells 
were positive for SOX-2 and MAP2, with a higher percentage immu-
nopositive for the marker of immature neural cells (SOX) than for 
mature neurons (MAP2), although the difference was not statistically 
significant. These results are consistent with phenotypic heteroge-
neity and indicate that retinoblastoma is composed of cells that ex-
press markers of both differentiated and undifferentiated cells(29). This 
heterogeneity should be considered when assessing the response of 
different cell types to potential therapeutic drugs.
Sakata et al. used nestin (a marker that decreases in expression 
with differentiation), HES-1 (a transcription factor regulating neu ronal 
development), and Chx10 (a regulator of proliferation and bi polar 
Table 2. Immunocytochemical expression of SOX-2, MAP2, and GFAP 
in retinoblastoma cell lines WERI-1 and Y79
Line SOX-2 MAP2 GFAP
WERI-1 3+ 2+ 0
Y79 2+ 2+ 0
SOX-2= sex determining region Y-box; MAP2= microtubule-associated protein; GFAP= 
glial fibrillary acidic protein.
Figure 3. Immunoexpression of GFAP. A) Negative immunostaining in tumor cells of a differentiated retinoblastoma 
but intense positivity in peritumoral glial cells (arrowhead) (×200). B) Negative immunostaining in tumor cells of an 
undifferentiated retinoblastoma with intense positivity in peritumoral glial cells (arrowhead) (×320). C) Negative 
immunostaining in tumor cells of an undifferentiated retinoblastoma with intense positivity in both peritumoral and 
sporadic intratumoral glial cells (arrows) (×200). D) Tumor cells located at the optic nerve (left side-arrowhead) are 
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cell development) to mark immature stem cells, and photorecep-
tor-specific nuclear receptor (PNR), GFAP, and MAP2 as markers of 
mature retinal cells. Five cases studied were positive for MAP2, while 
none were positive for GFAP, suggesting that these retinoblastomas 
originated from a post-mitotic neuronal cell lineage rather than 
a glial lineage, consistent without our observations. Seigel et al. 
detected subpopulations of retinoblastoma cells immunoreactive 
for various embryonic and neural stem cell markers and suggested 
that the persistence of stem cells may account for the typical early 
onset(30). In the current study, we found positive correlations between 
immunoexpression levels of SOX-2 and MAP2 and patient age at the 
time of enucleation, which supports the idea that retinoblastoma 
cells are more likely derived from neuronal stem cells in younger 
patients. While none of the cases showed substantial GFAP immuno-
reactivity within the tumor, reactive astrocytes showing strong GFAP 
expression were observed in the surrounding tissue accompanying 
intra- and peritumoral blood vessels. In contrast, unequivocal areas 
of reactive gliosis have been described in retinoblastoma, generally in 
the presence of a disorganized retina. According to Herman et al.(19), 
the reactive gliosis seen in continuity with retinoblastoma has a Müller 
cell proliferation pattern. In some cases, tumor growth causes the 
retina to rise, fold, and become disorganized, while in other tumors, 
retinal glia can be fully or partially surrounded by the tumor, resulting 
in the incorporation of isolated mature reactive astrocytes or small 
groups, as observed in a few of our cases. Our findings suggest that 
the retinoblastoma “cell of origin” does not express characteristics of 
mature glial cells or their direct precursors.
Numerous studies have also examined marker expression patterns 
in various retinoblastoma cell lines. Kyritsis et al.(10) speculated that 
retinoblastoma originates from a primitive neuroectodermal bi- or 
pluripotential cell based on findings that the Y79 retinoblastoma cell 
line expresses NSE and GFAP in the undifferentiated state and one of 
these two markers in a more differentiated state. A previous compa-
rative study on the immunohistochemical staining pattern of these 
two retinoblastoma cell lines found positivity for NSE, MAP2, homo-
logous gene class III β tubulin isotype (hβ4), and synaptophysin and 
negativity for opsin, GFAP, myelin basic protein, myelin-associated 
glycoprotein, and Leu7. The Y79 line is negative for H neurofilament 
protein (NFP-H) and S antigen, while the WERI-1 line is positive for 
both, suggesting that WERI-1 is in a more advanced state of diffe-
rentiation. Nonetheless, the presence of MAP2 immunoreactivity in 
both cell lines supports the hypothesis that both arise from mature 
neuroblasts(19). More recently, Seigel et al. reported the expression of 
stem cell markers in WERI-1 and Y79. This finding may have important 
clinical implications because stem cell properties could allow retino-
blastoma subpopulations to endure chemotherapy and retain tumor 
forming potential(30). In the present study, we observed that both Y79 
and WERI-1 lines were positive with varying intensity (moderate to 
intense) for SOX-2 and MAP2 and negative for GFAP, consistent with 
neuroblast origin. The presence of immature and mature neural 
markers in these lines corroborates our immunohistochemical fin-
dings and again suggests that retinoblastoma may originate from 
a multipotent neuronal cell lineage that retains some phenotypic 
heterogeneity. 
Two important aspects of this research are (1) the co-application 
of two neural markers (for immature and mature cells) and a broad 
spectrum glial marker in a relatively large sample of retinoblastoma 
cases, and (2) direct comparison with retinoblastoma cell lines. Ba-
sed on the heterogeneous phenotype of retinoblastoma, it may be 
necessary to design new treatment protocols using agents able to 
disrupt proliferation and destroy multiple subpopulations, including 
hybrid phenotypes.
In conclusion, the immunohistochemical expression of SOX-2 
and MAP2 in retinoblastoma indicates a neuroblast/neuronal origin, 
while GFAP negativity rules out a glial origin. No correlations were 
found between immunohistochemical expression levels (of SOX-2 
and MAP2) and prognostic factors, suggesting these are ubiquitous 
features of retinoblastoma. The immunocytochemical expression 
pattern of SOX-2, MAP2, and GFAP in retinoblastoma cell lines (Y79 
and WERI-1) further supports the neuroblast/neuronal origin of reti-
noblastoma.
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